BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 12518322)

  • 1. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
    Haese A; Graefen M; Becker C; Noldus J; Katz J; Cagiannos I; Kattan M; Scardino PT; Huland E; Huland H; Lilja H
    Prostate; 2003 Feb; 54(3):181-6. PubMed ID: 12518322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
    Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
    Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
    Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
    Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free and total human glandular kallikrein 2 in patients with prostate cancer.
    Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M
    Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
    Graefen M; Haese A; Pichlmeier U; Hammerer PG; Noldus J; Butz K; Erbersdobler A; Henke RP; Michl U; Fernandez S; Huland H
    J Urol; 2001 Mar; 165(3):857-63. PubMed ID: 11176486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
    Haese A; Becker C; Noldus J; Graefen M; Huland E; Huland H; Lilja H
    J Urol; 2000 May; 163(5):1491-7. PubMed ID: 10751864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
    Freedland SJ; Partin AW; Epstein JI; Walsh PC
    Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.